on the Alternative Investment Market of the London Stock Exchange (TXN.L).
The Company is focused on developing new methods for
manufacturing therapeutic proteins and a portfolio of products.
Its product pipeline includes Anti-Neoplastic Urinary Protein ("ANUP")
for the treatment of several types of cancer, Insulin and Human Serum
Albumin ("HSA"). The Company believes that its technology platform will
have multiple applications including the generation of transgenic chickens
for the manufacture of high volume therapeutic proteins, animal models for
the study of disease, and high throughput production of antibodies from
genomic derived targets for product identification. TranXenoGen is
developing its technology platform for the production of generic biologicals
(e.g., Insulin and HSA), contract manufacturing of third party products and
potential applications in the areas of biodefense and vaccine development.
In addition, the Company is exploring licensing of both the technology and
products for certain geographic areas and commercial applications.
NEWS CENTER I CAREERS I CONTACT US I DIRECTIONS
TRANXENOGEN, INC. • PO BOX 21 • NORTHBORO, MA. 01532 • 508 842 5036
© COPYRIGHT TRANXENOGEN, INC. 2002